NCT02462031UnknownPhase 1
A Randomized, Double-blind, Placebo-controlled, Single or Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
Kwang Dong Pharmaceutical co., ltd.1 site in 1 country38 target enrollmentStarted: March 2015Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 38
- Locations
- 1
- Primary Endpoint
- Pharmacokinetic parameters - Cmax
Study Overview
Brief Summary
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
Detailed Description
dose block-randomized, double-blinded, placebo controlled, single or multiple ascending dose study. AEs, PE, Vital signs, ECGs and Clinical lab tests
- Part I : multiple dose study (KD101 or placebo) / male and female
- Part II : single dose study (KD101) / male only
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 20 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or Female adults aged 20 to 55 at screening (Part II : Male adults aged 20 to 55 at screening)
- •Healthy volunteer whose BMI ≥ 27 (Part II : Healthy volunteer whose BMI ≥ 18)
- •Female who are not pregnancy possibility or Male/Female who can abstinence or contraception during clinical trials
Exclusion Criteria
- •Subjects who had clinically significant disease history (liver,kidney,nervous,pulmonary,endocrinal,urinary,cardiovascular,musculoskeletal,mental system,blood,tumor) or diagnosed within 1 month from screening
- •Subjects who had gastrointestinal disease(Crohn's disease, ulcer, acute/chronic pancreatitis) that affect the absorption of test drug or gastrointestinal operation (However, appendectomy, herniotomy induced by acute appendicitis are excluded)
- •Subjects who had following history. [myocardial infarction (diagnosed by cardiac enzyme and/or diagnostic ECG), cerebral infarction/stroke, arrhythmia needed to medical treatment, unstable angina, pulmonary hypertension]
- •Subjects who had positive result to Human Immunodeficiency Virus, Hepatitis B virus, Hepatitis C virus during screening
- •Subjects who had allergy history (ex. allergy for aspirin, antibiotics, etc) or had clinically-significant allergy
- •Subjects whose systolic BP was <85mmHg or >145mmHg, or diastolic BP was <50mmHg or >95mmHg, or pulse was >100/min after 3 minute-seating position. (BP can be re-measured twice at leat 5 minute-interval)
- •Subjects who would take prescribed/oriental drug(within 2 weeks from the first dosing day) or OTC drug or vitamines (within 1 weeks from the first dosing day)
- •Subjects who drink over than 21 unit (1 unit = 10g of pure alcohol) or cannot quit drinking alcohol during clinical trial period
- •Subjects who ate following food within 2 days from the first dosing day or cannot quit following food [grapefruit-contain food, caffein-contain food(coffee, green tea, black tea, soft drink, coffee milk, energy drink)]
- •Subjects who didn't agree contraception
- •Subjects who didn't agree to quit smoke
- •Subjects who donated his/her blood within 2 months (whole blood) / 1 month (apheresis) or who took transfusion within 1 month
- •Subjects who participated another clinical trials within 3 months from first dosing day. (The clinical trial completion day is defined as the last dosing day of past clinical trial)
- •Subjects who are not adequate to this trial by lab examination and another reasons
- •Subjects who weighed loss more than 5kg in 3 months
Arms & Interventions
KD101
Experimental
Intervention: KD101 (Drug)
KD101 placebo
Placebo Comparator
Intervention: placebo (Drug)
Outcomes
Primary Outcomes
Pharmacokinetic parameters - Cmax
Time Frame: up to 4 weeks
Cmax (Maximum concentration of drug in plasma)
Secondary Outcomes
- Pharmacodynamic parameters - PBMCs(up to 4 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male SubjectsDrug ToxicityNCT01979380Kwang Dong Pharmaceutical co., ltd.40
Completed
Phase 1
Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate DrugsArthritisNCT03876210PMG Pharm Co., Ltd47
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)Hepatitis CNCT00635804Merck Sharp & Dohme LLC60
Completed
Phase 1
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentHepatic ImpairmentNCT04166942Kadmon, a Sanofi Company35
Completed
Phase 1
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691Hepatitis C VirusNCT00810758Pfizer24